Vaxcyte (PCVX) Non-Current Assets (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Non-Current Assets of $1.5 billion for Q1 2026, down 7.63% year-over-year from $1.7 billion in Q1 2025, and up 11.59% quarter-over-quarter from $1.4 billion in Q4 2025.
Vaxcyte (PCVX) Non-Current Assets (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Non-Current Assets for 8 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 7.63% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (down 7.63% YoY), while the FY2025 annual figure was $1.4 billion, down 20.19% from the prior year.
- Non-Current Assets rose to $1.5 billion in Q1 2026 per PCVX's latest filing, from $1.4 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.7 billion in Q4 2024 and bottomed at $42.3 million in Q3 2022.
- Historically, Non-Current Assets has averaged $758.9 million across 5 years, with a median of $574.2 million in 2024.
- Annual changes were most pronounced in 2024 — Non-Current Assets surged 570.85% — and 2025, when it retreated 20.19%.
- Vaxcyte's Non-Current Assets stood at $63.6 million in 2022, then jumped by 390.33% to $312.0 million in 2023, then surged by 452.42% to $1.7 billion in 2024, then declined by 20.19% to $1.4 billion in 2025, then climbed by 11.59% to $1.5 billion in 2026.
- Business Quant data shows PCVX's Non-Current Assets at $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 1.59 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.59 Bn |
| Mar 31, 2026 | 1.53 Bn |
| Dec 31, 2025 | 1.38 Bn |
| Sep 30, 2025 | 1.40 Bn |
| Jun 30, 2025 | 1.59 Bn |
| Mar 31, 2025 | 1.66 Bn |
| Dec 31, 2024 | 1.72 Bn |
| Sep 30, 2024 | 1.35 Bn |
| Jun 30, 2024 | 605.79 Mn |
| Mar 31, 2024 | 574.23 Mn |
| Dec 31, 2023 | 311.96 Mn |
| Sep 30, 2023 | 200.62 Mn |
| Jun 30, 2023 | 192.50 Mn |
| Mar 31, 2023 | 167.49 Mn |
| Dec 31, 2022 | 63.62 Mn |
| Sep 30, 2022 | 42.31 Mn |
| Jun 30, 2022 | 47.89 Mn |
| Mar 31, 2022 | 60.49 Mn |
| Dec 31, 2021 | 67.99 Mn |
| Sep 30, 2021 | 51.12 Mn |